MA
Mark Andrew Ainsworth
Also known as: Mark Ainsworth, Mark A. Ainsworth
University of Southern Denmark, Odense Universitetshospital, University of Copenhagen, Danish Medicines Agency
Research areas: Medicine · Gastroenterology · Advanced Numerical Methods in Computational Mathematics · Inflammatory Bowel Disease · Rheumatoid Arthritis Research and Therapies
0000-0002-4899-1048
Employment
-
University of Southern Denmark Professor2021 - Present
-
Odense Universitetshospital Consultant Gastroenterologist2018 - Present
-
Danish Medicines Agency Chief medical Officer2018 - 2020
-
Herlev Hospital Head of Department2014 - 2018
-
Herlev Hospital Head of Medical Section2012 - 2014
-
University of Copenhagen Associate Clinical Professor2010 - 2018
-
Herlev Hospital Consultant Gastroenterologist2008 - 2012
-
Herlev Hospital Staff specialist2007 - 2008
-
Herlev Hospital Senior Registrar2004 - 2007
-
Ferring Lægemidler A/S Medical Director2004 - 2004
-
Herlev Hospital Senior House Officer2003 - 2004
-
Sjællands Universitetshospital Køge Senior House Officer2000 - 2001
-
Danish Medicines Agency Senior assessor, Head of section1998 - 2004
-
Glostrup Hospital Senior House Officer1997 - 1998
-
Herlev Hospital House Officer1997 - 1997
-
Glostrup Hospital Senior House Officer1995 - 1997
-
Odense University Hospital House Officer1994 - 1995
-
University of California, San Diego Research Fellow (Fogarty International Fellowship)1992 - 1994
-
Odense University Hospital House Officer1991 - 1992
-
University of Southern Denmark Research Fellow1988 - 1991
-
Odense University Hospital House Officer/Senior House Officer1986 - 1988
-
Kommunehospitalet House Officer1986 - 1986
Education
-
University of Copenhagen Teacher Training Program ( "Adjunktpædagogikum")2008 - 2009
- ? - 1986
Projects & Funding
-
Seponering af infliximab behandling hos patienter med Crohns sygdom i vedvarende komplet remission - Et dobbelt blindet, randomiseret, placebo kontrolleret, multicenterforsøg.” Danske Regioner2016 - 2020
-
Optimering af anti-TNF-alfa antistofbehandling baseret på farmakokinetiske forhold under graviditet hos patienter med inflammatorisk tarmsygdom Københavns Universitet2016 - 2018
-
Seponering af infliximab behandling hos patienter med Crohns sygdom i vedvarende komplet remission - Et dobbelt blindet, randomiseret, placebo kontrolleret, multicenterforsøg.” Herlev Hospital2016 - Present
-
Discontinuation of infliximab therapy in patients with Crohn's disease during sustained complete remission NordForsk2014 - 2020
-
Kvantificering af TNF-hæmmer og antistoffer mod TNF-hæmmer til optimering af biologisk behandling ved Crohn’s sygdom Herlev Hospital2012 - 2014
-
Kvantificering af TNF-hæmmer og antistoffer mod TNF-hæmmer til optimering af biologisk behandling ved Crohn’s sygdom Civilingeniør Frode V. Nyegaard og Hustrus Fond2010 - 2011
-
Kvantificering af TNF-hæmmer og antistoffer mod TNF-hæmmer til optimering af biologisk behandling ved Crohn’s sygdom Region Hovedstaden2010 - 2012
-
Kvantificering af TNF-hæmmer og antistoffer mod TNF-hæmmer til optimering af biologisk behandling ved Crohn’s sygdom P. Carl Petersens Fond2010 - 2013
-
Kvantificering af TNF-hæmmer og antistoffer mod TNF-hæmmer til optimering af biologisk behandling ved Crohn’s sygdom Herlev Hospitals Forskningsfond2009 - 2011
-
Individualised therapy versus dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial Aase og Ejnar Danielsens Fond2009 - 2011
-
Kvantificering af TNF-hæmmer og antistoffer mod TNF-hæmmer til optimering af biologisk behandling ved Crohn’s sygdom Colitis-Crohn Foreningen2009 - 2011
-
Seponering af infliximab behandling hos patienter med Crohns sygdom i vedvarende komplet remission - Et dobbelt blindet, randomiseret, placebo kontrolleret, multicenterforsøg.” Direktør Jacob Madsen og Hustru Olga Madsens Fond
Publications (218)
- Drug retention for advanced therapies for patients with ulcerative colitis and Crohn’s disease – a retrospective single center cohort study Save
- Baseline infliximab clearance identifies patients requiring intensified induction in acute severe ulcerative colitis Save
- Proactive Tight Monitoring of Patients with Inflammatory Bowel Disease in Biological Therapy: A Controlled Clinical Study (TIME IT) Save
- Personalised treatment in biologically naive patients with Crohn’s disease: a systematic review of the last 10 years Save
- Acute severe ulcerative colitis without systemic toxicity Save
- Acute Severe Ulcerative Colitis without systemic toxicity: a retrospective multicenter cohort study suggesting refining the definition of Acute Severe Ulcerative Colitis Save
- Extracellular matrix biomarkers may aid choice of advanced therapy sequencing to vedolizumab in patients with ulcerative colitis Save
- Extracellular matrix biomarkers may aid in choice of advanced therapy sequencing to vedolizumab in patients with Crohn's disease Save
- Extracellular matrix-derived biomarkers of mucosal damage and neutrophil activity are associated with vedolizumab failure in anti-TNF experienced patients with Ulcerative Colitis Save
- Genetic factors influencing risk of anti-drug antibody formation in inflammatory bowel disease Save
- Health-related quality of life impairment precedes manifestation of clinical relapse by seven weeks in patients with Crohn's disease discontinuing infliximab Save
- High baseline infliximab clearance in patients with acute severe ulcerative colitis predicts need for dose intensification to achieve treatment outcomes comparable to patients with low clearance Save
- Macrophage- and CD8+ T cell-conditioned media induce fibrogenesis, measured via type VI and I collagen formation, in a gastrointestinal Scar-in-a-Jar model Save
- The protocol of an independant, randomized, controlled, danish, multicenter trial of Model-informed precision dosing of ustekinumab and vedolizumab in inflammatory bowel disease Save
- Therapeutic Drug Monitoring of Ustekinumab and Vedolizumab in IBD: Expanding Flexibility Through PK-PD Time-Based Thresholds Save
- Therapeutic drug monitoring of ustekinumab and vedolizumab in Inflammatory Bowel Disease: A systematic review to define exposure thresholds for endoscopic remission Save
- MOdel-informed precision dosing (MIPD) of ustekinumab and VEdolizumab in inflammatory bowel disease: protocol for an Independent randomised, controlled, multicentre Trial (MOVE-IT) Save
- Adherence in the Treatment of Inflammatory Bowel Disease With Particular Focus on the Importance of the Clinical Pharmacist Save
- Skal patienter med inflammatorisk tarmsygdom tilbydes psykoterapi? Save
- Evaluation of point-of-care instrument for quantification of infliximab and adalimumab Save